Evidence map›Paper›PMID 41321036›Full record

ReviewACS biomaterials science & engineering2026

Antigen-Specific Inverse Vaccination Strategies Using Particle Systems for Multiple Sclerosis.

Kierstin A Clark, Nicole Rose Lukesh, Kristy M Ainslie

Abstract readReview
In one paragraph

Review in ACS biomaterials science & engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kierstin A ClarkDivision of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC, Chapel Hill, North Carolina27599, United States.
Nicole Rose LukeshDivision of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC, Chapel Hill, North Carolina27599, United States.ORCID 0000-0003-4030-1505
Kristy M AinslieDivision of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC, Chapel Hill, North Carolina27599, United States.ORCID 0000-0002-1820-8382

Funding

Biomaterials to study tolerance immune induction kineticsR01AI137525 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AINSLIE, KRISTY M · 2018 to 2022
$1.9M
Biodegradable polymeric microparticles comprised of acetalated dextran induce immune toleranceR01AI187725 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kristy M Ainslie · 2025 to 2026
$1.0M
NIAID NIH HHS R01 AI137525NIAID NIH HHS R01 AI187725
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects approximately 2.8 million people worldwide. In the United States alone, approximately 150 in every 100,000 people will develop MS ( Dilokthornsakul, P., et al.

Indexed as

Multiple SclerosisVaccinationVaccinesAnimalsHumansImmune ToleranceVaccinesantigen specific tolerancemicroparticlemultiple sclerosismyelin oligodendrocyte glycoproteinnanoparticleregulatory cells

Identifiers

PMID41321036
PMCPMC12671924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.